INDUSTRY NEWS


SECTION TITLE


chain. “By working together with the airline carriers, DHL ensures in-transit pharmaceutical product integrity. We are doing more than raising quality management standards; we are also supporting pharmaceutical manufacturers and medical institutions in their efforts to support everyday life.”


CenterWatch Joins WIRB-Copernicus Group


WIRB-Copernicus Group®, a provider of solutions that measurably improve the quality and efficiency of clinical research, has announced its acquisition of CenterWatch, a provider of clinical trial industry news and information, and the addition of Kenneth A. Getz, CenterWatch founder and owner, to its board of directors.


This acquisition will benefit the clinical trials industry, facilitating increased knowledge-sharing and communication among the key stakeholders in the clinical research environment: clinical trial sponsors, contract service providers, investigators, and study volunteers.


"We are delighted to welcome the passionate, highly-accomplished experts of the CenterWatch organization to our family of companies, and privileged to welcome Ken Getz to WCG's board of directors," said Donald A. Deieso, PhD, chairman and CEO of WCG. "In order for clinical research to function more efficiently, we must open up the pathways of communication and connectivity among its chief participants. Sponsors and contract research organizations (CROs) rely on investigators, investigators rely on willing patients, and patients and practitioners increasingly rely on technology- driven solutions to keep informed of relevant clinical trials. WCG and CenterWatch will contribute to the promising future of a well- integrated ecosystem providing unprecedented access to critical information and knowledge among all trial participants, and in so doing, make an even greater positive impact on the clinical research process."


"We are pleased and excited to join WCG, and to embark on our next stage of growth as a company and an information services provider," said Joan A. Chambers, chief operating officer of CenterWatch. "WCG shares our values and mission, and enthusiastically supports our independence and objectivity as a publisher of clinical trials information, data and analysis."


"WCG has made great strides in acquiring and integrating market leading assets," said Mr. Getz. "I look forward to serving on its board and to participating in its ongoing efforts to drive efficiency, quality and performance under a strategic vision of a truly patient-centric clinical research enterprise."


Mr. Getz is the chairman of CISCRP, a nonprofit organization that he founded to educate and raise public awareness of the clinical research process, and the director of sponsored programs and associate professor at the Tufts Center for the Study of Drug Development (CSDD) where he studies R&D management and operating models, investigative site, outsourcing and study volunteer trends and policies. Prior to founding CenterWatch, Mr. Getz assisted biopharmaceutical companies in developing and


implementing business strategies to improve clinical development performance. A well-known speaker at conferences, symposia, universities and corporations, Mr. Getz has published extensively in peer-reviewed journals, books and in the trade press. Mr. Getz holds a number of board appointments in the private and public sectors and is on the editorial boards of several journals.


Mr. Getz joins WCG's board of directors which includes other notable and accomplished members: James A. Bannon, PharmD, executive chairman of IndiPharm and former group president of Covance; Per Peterson, PhD, director of Life Technologies and former chairman of Johnson & Johnson Pharmaceutical Research & Development; and James Rothman, PhD, chairman of cellular biology at Yale University, the former chief science officer of GE Healthcare, and the recipient of the 2013 Nobel Prize in Medicine.


Crown Bioscience Strengthens Global Immuno-Oncology Platform with Immunophenotyping Service Offering


Crown Bioscience has announced the strengthening of its global Immuno-Oncology Platform at all its key facilities in Europe, USA, and Asia to support client’s needs with a comprehensive collection of validated models and services for in vivo pharmacodynamic and efficacy studies.


“In response to the growing demand for Immuno-Oncology translational services, CrownBio is now able to offer at its local facilities immunophenotyping analysis, including multi-color flow cytometry, immunohistochemistry and multiplex ELISA on our world-leading collection of Immuno-Oncology models, to rapidly profile and investigate the impact of experimental therapies on both murine and human immune systems,” said Jean Pierre Wery, President of Crown Bioscience.


CrownBio’s unique collections of well-characterized and validated syngeneic models profiled for checkpoint inhibitors, as well as the novel MiXeno™, MuPrime™, HuGEMM™ and humanized PDX platforms can all be extensively profiled using these immunophenotyping capacities for both pretreatment baseline and post treatment pharmacodynamic readouts to understand the impact on the immune system.


“In particular, single cell-based FACS analysis has become a standard and essential tool to investigate the impact of Immuno- Oncology therapy in both murine and humanized systems in the preclinical setting. Our ability to perform FACS analysis locally as part of our in vivo services offering will undoubtedly represent a key add-on technology for our clients” said Henry Li, Vice President of Translational Oncology at Crown Bioscience. “The ability to gate different sub-populations of T lymphocytes and myeloid compartment provides a rapid way for our clients to understand the impact of both single and combination therapies to significantly extend the reach of potential therapeutic effect across a larger population of patients,” continued Li.


pharmoutsourcing.com | 45 | July/August 2016


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54